Perrigo To Host Virtual Investor Meetings At The 2021 Barclays Global Consumer Staples Conference

DUBLIN, September 3, 2021 / PRNewswire / – Perrigo Company plc (NYSE; TASE: PRGO) today announced that Perrigo President and CEO, Murray S. Kessler, and CFO, Ray Silcock, are expected to attend investor meetings at the Barclays Global Consumer Staples Conference on. take part Thursday September 9th. The company will not make a formal presentation.

About Perrigo

Perrigo Company plc (NYSE; TASE: PRGO) is a leading provider of high quality, affordable self-care products and over-the-counter (OTC) health and wellness solutions that enhance individual wellbeing by enabling consumers to proactively prevent or control disease treat you can manage that yourself. Driven by its consumer self-care strategy, Perrigo is the largest OTC private label player in the US in the categories where it competes with more than 9,000 SKUs among consumer private label labels. In addition, Perrigo is a top 10 OTC company by sales in Europe, where more than 200 OTC branded products are marketed in 28 countries. Visit Perrigo online at www.perrigo.com.

Forward-Looking Statements

Certain statements in this press release are “forward-looking statements”. These statements relate to future events or the future financial performance of the company and involve known and unknown risks, uncertainties and other factors that could cause actual results, activities, performance or achievements of the company or its industry to differ materially from those expressed differ or are implied by forward-looking statements. In some cases, forward-looking statements can be identified using terms such as “may”, “will”, “could”, “would”, “should”, “expect”, “predict”, “plan”, “foresee,” “intend” The company has based these forward-looking statements on its current expectations, beliefs, estimates and projections. Although the company makes these expectations , Believes that assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the control of the company, including: the effects of the novel coronavirus (COVID-19) pandemic and the associated economic downturn and the impact on the supply chain on the company’s business; timing, amount and cost of share returns buy; future impairment losses; Customer acceptance of new products; Competition from other industry players, some of whom have greater marketing resources or market shares in certain product categories than the company; Price pressure from customers and consumers; Resolving uncertain tax positions, including the Company’s appeal against the Irish Revenue Service’s Investment Notices (“NoA”) and the Internal Revenue Service’s Draft and Definitive Notices (“NOPAs”) and the implications that any adverse outcome of any such proceeding would have on operating results, cash flows and liquidity; pending and potential third party claims and litigation, including litigation relating to alleged price fixing in the generics industry, alleged class and individual securities claims, and alleged product liability claims and litigation relating to uncertain tax positions, including the NoA and NOPAs; Developments in relation to any ongoing or future settlement negotiations regarding such claims or litigation; the potential impact of ongoing or future government investigations and initiatives; the potential cost and reputational impact of product recalls or sales stops; the impact of tax reform legislation and health policy; general economic, credit and market conditions; Fluctuations in exchange rates and interest rates; the success of the Rx business sale, including the ability to obtain the anticipated benefits therefrom; the risk that any potential costs or liabilities incurred or withheld in connection with the transaction exceed the Company’s estimates or adversely affect the business or affect the operations of the company; the completion and success of other announced acquisitions or disposals and the Company’s ability to obtain the desired benefits therefrom; our ability to meet its debt clauses and the ability of the company to carry out announced cost-cutting, strategic and other initiatives and obtain the desired benefits. An adverse outcome in relation to our appeal against material outstanding tax assessments or pending litigation, including securities or drug pricing matters, could ultimately result in the use of Company assets to pay such assessments, third party claims for damages and related interest and / or penalties, and such use of Corporate assets would limit the assets available for other corporate purposes. These and other important factors, including those discussed under “Risk Factors” on the Company’s Form 10-K for the past year December 31, 2020 and in all subsequent filings with the Securities and Exchange Commission, actual results, performance or achievements could differ materially from those expressed or implied in these forward-looking statements. The forward-looking statements in this press release speak only as of the date of this press release, and unless otherwise required by applicable securities laws, the company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Perrigo Company plc

similar links

http://www.perrigo.com